Information is solely for medical professionals
Beifuxin Gel
Bovine Basic Fibroblast Growth Factor Gel
/
Specification 21000IU/5g and 42000IU/10g
Beifuxin gel is a genetically engineered new drug developed and manufactured by Zhuhai Essex Bio-Pharmaceutical Co., Ltd..
The API of Beifuxin is recombinant bovine basic fibroblast growth factor (rb-bFGF) - a multifunctional growth factor with a wide range of bioactivity, which can stimulate the proliferation and differentiation of cells involved in wound healing.
The API of Beifuxin is recombinant bovine basic fibroblast growth factor (rb-bFGF) - a multifunctional growth factor with a wide range of bioactivity, which can stimulate the proliferation and differentiation of cells involved in wound healing.
Mechanism
The API of Beifuxin is recombinant bovine basic fibroblast growth factor (rb-bFGF), which can stimulate the repair and regeneration of tissues and cells derived from the mesoderm and ectoderm (such as epithelial cells, dermal cells, fibroblasts, vascular endothelial cells, osteoblasts, nerve cells etc.). The specific combination of rb-bFGF with the wounded target cell surface can trigger the cells to repair actively and stimulate cell division, proliferation, migration and differentiation, so as to accelerate wound healing and improve the healing quality.
Features
· A new water-soluble gel that can control the release of the active ingredient
· Accelerate wound healing
· Shortening the healing time and reduce scar formation
· Safe and effective treatment without any side effect
· Accelerate wound healing
· Shortening the healing time and reduce scar formation
· Safe and effective treatment without any side effect
Clinical Application
· Burn and scald wounds: including shallow II degree and deep II degree wounds, granulation wounds and inhalation injuries.
· Acute wounds: bruises, contusions, combined injuries and cuts.
· Surgical incisions: incisions of surgery, orthopedics, gynaecology (such as lateral episiotomy and cesarean incision), otolaryngology, urology and proctology.
· Chronic wounds: diabetic ulcers, vascular ulcers, radiochemotherapy ulcers, bedsores, fistulas, residual wounds and cervical erosions.
· Skin grafting: skin donor site, skin grafting site, skin flap handling.
· Other applications: after plastic surgery, skin resurfacing, dermabrasion, nevus removal and laser therapy wounds.
· Acute wounds: bruises, contusions, combined injuries and cuts.
· Surgical incisions: incisions of surgery, orthopedics, gynaecology (such as lateral episiotomy and cesarean incision), otolaryngology, urology and proctology.
· Chronic wounds: diabetic ulcers, vascular ulcers, radiochemotherapy ulcers, bedsores, fistulas, residual wounds and cervical erosions.
· Skin grafting: skin donor site, skin grafting site, skin flap handling.
· Other applications: after plastic surgery, skin resurfacing, dermabrasion, nevus removal and laser therapy wounds.
NDRL
《National Drug List for Basic Medical Insurance, Work Related Injury Insurance and Maternity Insurance (2023)》
Medical Guidelines
· Chinese Dermatologist Consensus about Application of Recombinant Bovine Basic Fibroblast Growth Factor (rb-bFGF) for Laser and IPLS Treatment and Skin Barrier Repairment (2019)
· Clinical Guidelines for Use of Exogenous Growth Factors in Skin Wounds, Chin J Burns (2017)
· Expert Advice on Diagnosis and Treatment of Pemphigus Vulgaris (2016)
· Chinese Guidelines for Diagnosis and Treatment of Skin Wounds (2015)
· Clinical Guidelines for Use of Exogenous Growth Factors in Skin Wounds, Chin J Burns (2017)
· Expert Advice on Diagnosis and Treatment of Pemphigus Vulgaris (2016)
· Chinese Guidelines for Diagnosis and Treatment of Skin Wounds (2015)
粵公網安備 44049102496184號